Subject
Pharmacology,Immunology,Immunology and Allergy
Reference83 articles.
1. Myocarditis following the use of different immune checkpoint inhibitor regimens: a real-world analysis of post-marketing surveillance data;Fan;Int. Immunopharmacol.,2019
2. Immuno-oncology: the third paradigm in early drug development;Martin-Liberal;Target. Oncol.,2017
3. ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial;Wrangle;Lancet Oncol.,2018
4. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial (vol 19, pg 940, 2018);Zhu;Lancet Oncol.,2018
5. Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial;Atkins;Lancet Oncol.,2018
Cited by
44 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献